RGLS

Regulus Therapeutics Inc. [RGLS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RGLS Stock Summary

Top 10 Correlated ETFs

RGLS

Top 10 Correlated Stocks

RGLS

In the News

RGLS Financial details

Company Rating
-
Market Cap
183.3M
Income
-29.99M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.87
Forward P/E
-
PEG
0.6
P/S
-
P/B
0.89
P/C
-
P/FCF
-0.94
Quick Ratio
3.73
Current Ratio
4.25
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.59
EPS next Y
-
EPS next Q
-
EPS this Y
-15.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-31.88%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
100%
SMA50
100%
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
-76%
ROE
-94%
ROC
-1.01%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.08-3.79
52W High
-33.5%
52W Low
+99.5%
RSI
67
Rel Volume
0.13
Avg Volume
3.14M
Volume
395.56K
Perf Week
15.99%
Perf Month
50%
Perf Quarter
38.54%
Perf Half Y
27.07%
-
-
-
-
Beta
1.549
-
-
Volatility
0.09%, 0.24%
Prev Close
-3.16%
Price
1.995
Change
3.91%

Something similar

Top by Market Cap
ABEC.DE
JPM
NVDA
APC.DE
FB2A.DE
Top Correlated ETFs
L8I3.DE
ITEH.L
IAGG
EXHE.DE
IS0M.DE
Top Correlated Stocks
BKTI
MTL.L
GFASY
002294.SZ
NXT.L
Similar Market Cap
0AR9.L
OPER
EWD
8657.HK
0111.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 3.14M
  • Market Capitalization 183.3M
  • Employee 30
  • CEO Mr. Joseph P. Hagan M.B.A.
  • Headquarters San Diego,CA,US
  • IPO Date 2012-10-09
  • Website https://www.regulusrx.com

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.